Post hoc analysis of SURMOUNT-OSA (adults with moderate-to-severe OSA and obesity): tirzepatide improved patient-reported outcomes more than placebo across symptom subgroups, with numerically larger gains in those with worse baseline fatigue, sleepiness or sleep quality.
Secondary analysis
Kanu et al. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses